The Indian pharmaceutical market accounts for more than 10% of global drug production.

It is one of the country’s biggest employers, with more than 340,000 Indian employees dedicated to an industry that is worth in excess of $22 billion, and pharmaceutical exports of some $14.7 billion in 2013, with 55% heading to highly regulated Western markets.

Zydus Cadila, a fully integrated, global healthcare provider and the fifth largest pharmaceutical company in India, recently decided to improve its solid oral dosage form production processes for potent drugs. And, wishing to implement high containment equipment, they approached GEA.

GEA was able to supply the company with a complete oncology manufacturing line. The entire project was managed in-house, beginning with a risk analysis and progressing through design, installation and start-up. By choosing fully equipped UltimaPro™ 10 and 75 single pot processors, Hicoflex® technology and BUCK® MC valves, Zydus Cadila has ensured that it will be able to produce its OEB 3 and 4 drugs in a safe, cGMP-compliant environment and guarantee maximum yields with reduced cycle times. GEA didn’t just supply a complete oncology manufacturing line, it also ensured the health and safety of the operators.

With 10,500 manufacturing units and more than 3,500 pharmaceutical companies in India, the sector is growing at an exceptional rate. GEA believes that India is the right place to be, right now. GEA technical and sales experts will be available at P-MEC, Mumbai (Hall 5, i26).

more about GEA pharma systems